Article
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer
22 Jan 2025
Abstract excerpt
BACKGROUND: Lu-prostate-specific membrane antigen (PSMA)-617 (LuPSMA) is a radionuclide therapy approved for patients with PSMA-avid metastatic castrate-resistant prostate cancer (mCRPC). We evaluated whether alterations in the DNA damage repair (DDR) pathway were associated with outcomes to LuPSMA. PATIENTS AND METHODS: We identified an institutional cohort of men (n = 134) treated with ≥2 cycles of LuPSMA who...